Activators of Angiogenesis and Cardiovascular Diseases. Results of Study of Blood Levels of Vascular Endothelial Growth Factor and Angiopoetin-2 in Patients with Essential Hypertension

S.M. Koval, O.V. Mysnichenko, I.O. Snegurskaya, O.V. Vysotskaya, O.I. Tsigankov, I.A. Korneychuk, M.Yu. Penkova

Abstract


Blood levels of vascular endothelial growth factor and angiopoetin-2, powerful activators of angiogenesis with proinflammatory activity were studied in hypertensive patients. Significantly higher vascular endothelial growth factor and angiopoetin-2 blood levels have been determined in hypertensive patients compared to normotensive control subjects. The blood levels of angiopoetin-2 were found to be enhanced in hypertensive patients while deterioration of essential hypertensive and at presence of such metabolic disorders as abdominal obesity, fasting hyperglycemia, glucose intolerance, hyperuricemia and combined dyslipidemia. Vascular endothelial growth factor blood levels were higher in hypertensive patients with stable angina pectoris compared to the patients without angina pectoris. The data obtained indicate an important role of angiogenesis activation in the development of essential hypertension and its cardiovascular complications.


Keywords


essential hypertension; angiogenesis; vascular endothelial growth factor; angiopoetin-2; inflammation

References


Гавриленко Т.И., Рыжкова Н.А., Пархоменко А.Н. Сосудистый эндотелиальный фактор роста в клинике внутренних заболеваний и его патогенетическое значение // Укр. кард. журнал. — 2011. — № 4. — С. 87-95.

Серцево-судинні захворювання. Рекомендації з діагностики, профілактики та лікування // За ред. В.М. Коваленка, М.І. Лутая. — К.: Моріон, 2011. — 400 с.

Borona E., Targher G., Alberiche M. et al. Homeostasis Model Assessment Closely Mirrors the Glucose Clamp Technique in the Assessment of Insulin Sensitivity // Diabet. Care. — 2000. — Vol. 23. — P. 57-64.

Chen C.H., Walterscheid J.P. Plaque angiogenesis versus compensatory arteriogenesis in atherosclerosis // Circ. Res. — 2006. — Vol. 99. — P. 787-789.

2013 ESH/ESC Guidelines for management of arterial hypertension // J. of Hypertension. — 2013. — № 31. — Р. 1281-1357.

Fiedler U., Reiss Y., Scharpfenecker M. et al. Angiopoetins: a link between angiogenesis and inflammation // Trend. Immunol. — 2006. — Vol. 27. — P. 552-558.

Hiyama T., Tanaka T., Endo S. et al. Angiogenesis in athe­rosclerotic plaque obtained from carotid endarterectomy: association between symptomatology and plaque morphology // Neurol. Med. Chir. — 2010. — Vol. 50. — P. 1056-1061.

Holash J., Davis S., Papadopoulos N. VEGF-Trap: A VEGF blocker with potent antitumor effects // PNAS. — 2002. — Vol. 99, № 17. — P. 1393-1398.

Hughes C.C. Endothelial-stromal interaction in angioge­nesis // Curr. Opin. Hematol. — 2008. — Vol. 15. — P. 204-209.

Iribarren C., Phelps B.H., Darbinian J.A. et al. Circula­ting angiopoietins-1 and -2, angiopoietin receptor Tie-2 and vascular endothelial growth factor-A as a biomarkers of acute myocardial infarction: a prospective nested case-control study // BMS Cardivasc. Disord. — 2011. — Vol. 11, № 31. — Р. 11-31.

Korff T., Ernst E., Nobiling R. et al. Angiopoetin-1 mediates inhibition of hypertension-induces release of angiopetin-2 from endothelial cells // Cardiovascular Research. — 2012. — Vol. 94. — P. 510-518.

Khurana R., Simons M., Martin G. et al. Role of angiogenesis in cardiovascular disease: a critical appraisal // Circulation. — 2005. — Vol. 112. — P. 1813-1824.

Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis // Nature. — 2011. — Vol. 473. — P. 317-332.

Lieb W., Safa R., Benjamin E.J., Xanthakis V. et al. Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function // European Heart Journal. — 2009. — Vol. 30. — Р. 1121-1127.

Steeghs N., Gelderblom H., Roodt J.O. et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor // Clin. Cancer Res. — 2008. — Vol. 14. — P. 3470-3476.

Struijker-Boudier H.A.J., Agabiti-Rosei E. The microcirculation and the haemodynamics of hypertension // ESH Clinical Practice Newsletters. — 2011. — P. 67-68.

Zachary I., Morgan R.D. Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects // Heart. — 2011. — Vol. 97. — P. 181-189.

Zhang W., Doherty M., Pascual E. et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) // Ann. Rheum. Dis. — 2006. — Vol. 65. — P. 1301-1311.

Zhang J., Silva T., Yarivinsky T. et al. VEGF Blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling // Circ. Res. — 2010. — Vol. 107. — P. 408-417.




DOI: https://doi.org/10.22141/2224-1485.6.50.2016.89774

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru